SynthesisNutrients2026
The Therapeutic Potential of Berry-Derived and Berry-Based Interventions in Inflammatory Bowel Disease: A Comprehensive Systematic Review of Preclinical and Clinical Evidence.
Synthesis in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
introductionBerry-derived and berry-based interventions have gained increasing attention for their potential health benefits. Berries are rich in diverse bioactive compounds, including polyphenols and anthocyanins, which are associated with a broad range of biological activities, particularly antioxidant and anti-inflammatory effects. Over the last decade, numerous studies have focused on berries, particularly those from the Ericaceae family (blueberry, cranberry and bilberry), the Solanaceae family (goji berry,
methodsA systematic literature search was conducted using PubMed, Web of Science, and Scopus databases. Specific inclusion and exclusion criteria were applied to identify relevant articles published up to July 2026. After the removal of duplicates and a thorough screening of titles, abstracts, and full texts, a total of 19 studies were included, comprising 16 studies conducted on animal models and 3 clinical studies involving patients. The 3 clinical studies corresponded to 5 publications and involved a total of 68 unique participants, as two publications were secondary analyses of the same patient cohorts. These investigations evaluated the possible effects of berry-derived and berry-based interventions in both experimental models and clinical settings.
resultsPreclinical studies suggested potential protective effects against intestinal inflammation by reducing pro-inflammatory cytokines, improving epithelial barrier integrity, and restoring gut microbiota composition. The included clinical studies reported improvements in disease activity, fecal calprotectin levels, quality of life, and remission rates in patients with ulcerative colitis. Nevertheless, the available clinical evidence remains limited and heterogeneous, preventing definitive conclusions regarding clinical efficacy.
conclusionsThe current clinical data should therefore be considered preliminary. Larger and more rigorous randomized controlled trials are needed to determine whether the biological effects observed in preclinical models translate into clinically relevant benefits in patients with IBD. Overall, preclinical evidence complements clinical findings by providing mechanistic insights that help contextualize and interpret outcomes observed in human studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.